Search

Your search keyword '"Abravanel, Florence"' showing total 15 results
Start Over Author "Abravanel, Florence" Publisher american society for microbiology
15 results on '"Abravanel, Florence"'

1. Characterization of virus‒host recombinant variants of the hepatitis E virus

Author

Paronetto, Olivia, primary, Allioux, Claire, additional, Diméglio, Chloé, additional, Lobjois, Lhorane, additional, Jeanne, Nicolas, additional, Ranger, Noémie, additional, Boineau, Jérôme, additional, Pucelle, Mélanie, additional, Demmou, Sofia, additional, Abravanel, Florence, additional, Chapuy-Regaud, Sabine, additional, Izopet, Jacques, additional, and Lhomme, Sébastien, additional

Published
2024
Full Text
View/download PDF

4. Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy

Author

Lhomme, Sebastien, primary, Kamar, Nassim, additional, Nicot, Florence, additional, Ducos, Jacques, additional, Bismuth, Michael, additional, Garrigue, Valerie, additional, Petitjean-Lecherbonnier, Joelle, additional, Ollivier, Isabelle, additional, Alessandri-Gradt, Elodie, additional, Goria, Odile, additional, Barth, Heidi, additional, Perrin, Peggy, additional, Saune, Karine, additional, Dubois, Martine, additional, Carcenac, Romain, additional, Lefebvre, Caroline, additional, Jeanne, Nicolas, additional, Abravanel, Florence, additional, and Izopet, Jacques, additional

Published
2016
Full Text
View/download PDF

5. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin

Author

Larrat, Sylvie, primary, Vallet, Sophie, additional, David-Tchouda, Sandra, additional, Caporossi, Alban, additional, Margier, Jennifer, additional, Ramière, Christophe, additional, Scholtes, Caroline, additional, Haïm-Boukobza, Stéphanie, additional, Roque-Afonso, Anne-Marie, additional, Besse, Bernard, additional, André-Garnier, Elisabeth, additional, Mohamed, Sofiane, additional, Halfon, Philippe, additional, Pivert, Adeline, additional, LeGuillou-Guillemette, Hélène, additional, Abravanel, Florence, additional, Guivarch, Matthieu, additional, Mackiewicz, Vincent, additional, Lada, Olivier, additional, Mourez, Thomas, additional, Plantier, Jean-Christophe, additional, Baazia, Yazid, additional, Alain, Sophie, additional, Hantz, Sebastien, additional, Thibault, Vincent, additional, Gaudy-Graffin, Catherine, additional, Bouvet, Dorine, additional, Mirand, Audrey, additional, Henquell, Cécile, additional, Gozlan, Joel, additional, Lagathu, Gisèle, additional, Pronier, Charlotte, additional, Velay, Aurélie, additional, Schvoerer, Evelyne, additional, Trimoulet, Pascale, additional, Fleury, Hervé, additional, Bouvier-Alias, Magali, additional, Brochot, Etienne, additional, Duverlie, Gilles, additional, Maylin, Sarah, additional, Gouriou, Stéphanie, additional, Pawlotsky, Jean-Michel, additional, and Morand, Patrice, additional

Published
2015
Full Text
View/download PDF

14. Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy.

Author

Lhomme S, Kamar N, Nicot F, Ducos J, Bismuth M, Garrigue V, Petitjean-Lecherbonnier J, Ollivier I, Alessandri-Gradt E, Goria O, Barth H, Perrin P, Saune K, Dubois M, Carcenac R, Lefebvre C, Jeanne N, Abravanel F, and Izopet J

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Base Sequence, Child, Female, Genetic Markers, Hepatitis E virology, Humans, Male, Middle Aged, Mutation genetics, RNA, Viral genetics, Sequence Analysis, RNA, Treatment Outcome, Young Adult, Antiviral Agents therapeutic use, Hepatitis E drug therapy, Hepatitis E virus drug effects, Hepatitis E virus genetics, RNA-Dependent RNA Polymerase genetics, Ribavirin therapeutic use
Abstract

Hepatitis E virus (HEV) can lead to chronic infection in solid-organ transplant patients. Ribavirin is efficient for treatment of chronically infected patients. Recently, the1634R mutation in the HEV polymerase has been associated with treatment failure. However, it is unclear if this mutation can be used as a prognostic marker of treatment outcome. We studied the prevalence of the 1634R mutation in the HEV polymerase of patients starting ribavirin therapy, the influence of the 1634R variants on the viral response, the frequency of the 1634R mutation in patients whose treatment failed, and its impact on ribavirin retreatment. We analyzed pretreatment samples from 63 solid-organ transplant patients with chronic hepatitis E using deep sequencing; 42 patients had a sustained virologic response (SVR), and 21 were non-SVR patients. We detected the 1634R variant by deep sequencing in 36.5% (23/63) of the patients (proportions, 1.3 to 100%). The 1634R variant was detected in 31.0% (13/42) of baseline plasma samples from patients with SVR and in 47.6% (10/21) in the other patients (P = 0.2). The presence of this mutation did not influence the initial decrease in viral RNA. Lastly, a second prolonged ribavirin treatment led to SVR in 70% of the patients who initially did not have SVR, despite the presence of the 1634R variant. We conclude that the presence of the 1634R variant at ribavirin initiation does not lead to absolute ribavirin resistance. Although its proportion increased in patients whose treatment failed, the presence of the 1634R variant did not compromise the response to a second ribavirin treatment., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)

Published
2015
Full Text
View/download PDF

15. Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Author

Vallet S, Larrat S, Laperche S, Le Guillou-Guillemette H, Legrand-Abravanel F, Bouchardeau F, Pivert A, Henquell C, Mirand A, André-Garnier E, Giordanengo V, Lagathu G, Thibault V, Scholtes C, Schvoerer E, Gaudy-Graffin C, Maylin S, Trimoulet P, Brochot E, Hantz S, Gozlan J, Roque-Afonso AM, Soussan P, Plantier JC, Charpentier C, Chevaliez S, Colson P, Mackiewicz V, Aguilera L, Rosec S, Gouriou S, Magnat N, Lunel-Fabiani F, Izopet J, Morand P, Payan C, and Pawlotsky JM

Subjects
Amino Acid Sequence, Antiviral Agents chemistry, Base Sequence, Genotype, Hepacivirus enzymology, Mutation, Protease Inhibitors chemistry, Quality Control, Sequence Analysis, DNA, Antiviral Agents pharmacology, Drug Resistance, Viral genetics, Hepacivirus drug effects, Hepacivirus genetics, Protease Inhibitors pharmacology, Viral Nonstructural Proteins genetics
Abstract

Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple-therapy breakthrough. This multicenter quality control study evaluated the expertise of 23 French laboratories in HCV protease inhibitor resistance genotyping. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical strains, and one HCV RNA-negative sample was provided to the participating laboratories. The results showed that any laboratory with expertise in sequencing techniques should be able to provide reliable HCV protease inhibitor resistance genotyping. Only a 0.7% error rate was reported for the amino acid sites studied. The accuracy of substitution identification ranged from 75% to 100%, depending on the laboratory. Incorrect results were mainly related to the methodology used. The results could be improved by changing the primers and modifying the process in order to avoid cross-contamination. This study underlines the value of quality control programs for viral resistance genotyping, which is required prior to launching observational collaborative multicenter studies on HCV resistance to direct-acting antiviral agents.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results